No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BPMC240621C100000
- 4.93
- -3.61-42.27%
15min DelayClose Jun 18 15:59 ET
4.93High4.40Low
4.40Open8.54Pre Close3 Volume74 Open Interest100.00Strike Price1.43KTurnover0.00%IV-1.67%PremiumJun 21, 2024Expiry Date6.71Intrinsic Value100Multiplier2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma15.93Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Investing in Blueprint Medicines (NASDAQ:BPMC) a Year Ago Would Have Delivered You a 78% Gain
The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by picking above-average stocks. To wit, the Blueprint Medicines Corporation (NASDA
Unusual Options Activity: APA, LNG and Others Attract Market Bets, APA V/OI Ratio Reaches 420.0
EST Jun 11th Morning Delivery - In the last two hours of trading, 9 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.O
Wells Fargo Maintains Blueprint Medicines(BPMC.US) With Buy Rating
Wells Fargo analyst Derek Archila maintains $Blueprint Medicines(BPMC.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 40.2% and a total average return of 5.6% over
Insider Sale: Chief Scientific Officer Percy Carter Sells Shares of Blueprint Medicines Corp (BPMC)
Blueprint Medicines(BPMC.US) Officer Sells US$420.52K in Common Stock
$Blueprint Medicines(BPMC.US)$ Officer Carter Percy H. sold 4,000 shares of common stock on Jun 5, 2024 at an average price of $105.13 for a total value of $420.52K.Source: Announcement What is statem
Blueprint Medicines Insider Sold Shares Worth $420,520, According to a Recent SEC Filing
Percy H. Carter, Chief Scientific Officer, on June 05, 2024, sold 4,000 shares in Blueprint Medicines (BPMC) for $420,520. Following the Form 4 filing with the SEC, Carter has control over a total of
Comments
$SPDR S&P Biotech ETF(XBI.US$
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x % $Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x % $Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
3
Insiders selling shares without any recorded purchases over the last year raises caution. The alignment between management and smaller shareholders due to insider ownership is not outstanding. Caution is advised before buying shares in Blueprint Medicines due to significant selling activity.
3
The stock's commendable performance is tied to revenue growth. However, profitability and cash flow checks are crucial for future views. Given the strong share price momentum, the stock warrants a closer look.
Blueprint Medicines' high P/S ratio is worrisome due to its lower projected growth compared to the broader industry. If future revenues don't support this optimism, the current high P/S ratio may not be sustainable. Prices may not be reasonable unless conditions significantly improve.
1
Read more